N-Acetylcysteine (NAC) has the strongest evidence base of any supplement for cannabis use disorder. This is a high bar because the evidence base for cannabis cessation supplements is generally thin-but NAC clears it with three randomized controlled trials, two of which are published in high-impact journals.
The Mechanistic Rationale
Cannabis dependence, like nicotine dependence, involves dysregulation of the glutamate system in addiction circuitry. Chronic THC use alters glutamate transmission in the nucleus accumbens and prefrontal cortex, particularly by reducing activity of the cystine-glutamate antiporter (xCT) that maintains extracellular glutamate homeostasis.
When xCT function is reduced:
- Basal extracellular glutamate decreases
- Phasic glutamate responses to drug cues are exaggerated relative to tonic glutamate
- This creates a biological substrate for intense, cue-triggered craving
NAC restores xCT function by providing cysteine substrate for the antiporter, normalizing basal glutamate tone and reducing cue-triggered craving intensity. The mechanism is the same as for nicotine (glutamate dysregulation is a common feature of addiction), but the clinical evidence is stronger for cannabis.
The Clinical Trials
Gray et al. (2012): A randomized, double-blind, placebo-controlled trial in cannabis-dependent adolescents and young adults. NAC 1200mg twice daily vs. placebo during a cessation attempt with contingency management. NAC group showed significantly higher cannabis abstinence rates (odds ratio 2.4) and significantly reduced craving scores.
Tomko et al. (2018): NAC augmentation of a behavioral intervention for cannabis use disorder in adults. NAC 2400mg daily produced significant reductions in cannabis use and craving compared to placebo.
Roten et al. (2022): NAC combined with mindfulness-based intervention in cannabis use disorder. NAC group showed significant improvements in abstinence and craving compared to placebo.
Three trials. Consistent direction of effect. Replicated across different populations and study designs.
Dose Considerations
The clinical trials used doses of 1200-2400mg daily (divided doses), which is higher than the 600mg 2x (1200mg/day) in the GREEN protocol. The 1200mg/day dose is at the low end of trial doses and the most common well-tolerated dose. Higher doses can produce gastrointestinal side effects (nausea, diarrhea) that reduce compliance.
The GREEN protocol uses 600mg twice daily as a balance between efficacy and tolerability. If GI side effects are not an issue, some users increase to 900mg twice daily based on trial evidence.
When Does It Start Working?
NAC's effect on glutamate homeostasis develops over 1-2 weeks of consistent use. Users should not expect immediate craving reduction. The intervention is foundational-it establishes the neurochemical substrate for reduced cue reactivity.
The most reported subjective effect: cravings are present but less urgent. The time between the craving signal and the behavioral response to it lengthens-and that gap is where cessation happens.
The Combination Logic
NAC + Magnesium L-Threonate + DHA/EPA forms the core of the GREEN protocol's neurochemical stack:
- NAC: glutamate homeostasis (reduces craving intensity)
- Magnesium L-Threonate: sleep support + cognitive recovery
- DHA/EPA: endocannabinoid substrate (supports ECS recovery)
Each addresses a different mechanism of cannabis withdrawal. Together, they form the most mechanistically comprehensive cannabis cessation supplement intervention currently available.